跳至主要内容
临床试验/NCT04336254
NCT04336254Unknown1 期

Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial

Renmin Hospital of Wuhan University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2020年5月6日最近更新:
适应症

试验速览

阶段
1 期
入组人数
20
试验地点
1
主要终点
TTCI

研究概览

简要总结

This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.

详细描述

This clinical trial is set out to evaluate the followings:

  1. the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19;
  2. to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and
  3. to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 18-65 years;
  • Voluntarily participate in this clinical trial and sign off "informed consent form";
  • Diagnosed with severe pneumonia of COVID: respiratory distress, RR >30 times / min; resting oxygen saturation of 93% or less; arterial partial pressure of oxygen / oxygen concentration 300mmHg; SARS-CoV-2 nucleic acid test was positive.
  • Chest imaging confirm COVID-19 featured lesions in lung.

排除标准

  • Receive any clinical trial drug treatment for COVID-2019 within 30 days before the screening assessment;
  • Severe liver disease (e.g., Child Pugh score >=C or AST> 5 times of the upper limit);
  • Patients with known severe renal insufficiency (estimated glomerular filtration rate <=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis;
  • Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses;
  • Female patients who have no sexual protection in the last 30 days prior to the screening assessment;
  • Pregnant or lactating women or women using estrogen contraception;
  • Patients who are planning to become pregnant during the study period or within 6 months after the end of the study period;
  • Other conditions that the researchers consider not suitable for participating in this clinical trial.

结局指标

主要结局

TTCI

时间窗: 1-28 days

Time to Clinical Improvement

次要结局

  • SPO2(1-28 days)
  • Lung lesion(1-28 days)
  • Body temperature(1-28 days)
  • Blood test(1-28 days)
  • Side effects in the treatment group(1-28 days)
  • Immune function(1-28 days)
  • C-reactive protein (mg/L)(1-28 days)
  • Time of SARS-CoV-2 clearance(1-28 days)
  • RR(1-28 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ye Qingsong

Professor, Director

Renmin Hospital of Wuhan University

研究点 (1)

Loading locations...

相似试验